微信公众号

官网二维码
中国癌症防治杂志

中国癌症防治杂志 ›› 2013, Vol. 5 ›› Issue (4): 328-332.doi: 10.3969/j.issn.1674-5671.2013.04.10

• 临床研究 • 上一篇    下一篇

检测淋巴结中ERCC1蛋白指导非小细胞肺癌的个体化治疗

  

  1. 南京医科大学附属无锡市人民医院呼吸科
  • 出版日期:2013-12-25 发布日期:2013-12-31
  • 通讯作者: 朱建荣 E-mail:zhu_wuxi@sina.com

Detection of ERCC1 protein in lymph nodes for guiding individualized therapy in advanced non-small cell lung cancer

  • Online:2013-12-25 Published:2013-12-31

PDF (PC)

528

赞

被引次数

5

摘要： 目的 探讨转移淋巴结中核苷酸切除修复交叉互补基因1（excision repair cross-complementation group1， ERCC1）蛋白的表达情况，以指导非小细胞肺癌（non-small cell lung cancer，NSCLC）进行个体化治疗的价值。方法 96例通过淋巴结病理组织检查确诊为NSCLC的患者，分为标准治疗组38例，选择含铂类药物的一线化疗方案化疗；个体化治疗组58例，根据转移淋巴结组织中ERCC1蛋白的表达情况选择个体化化疗方案治疗。分析比较两个治疗组的化疗效果，以Kaplan-Meier法分析两个治疗组患者生存期的差异。结果 在患者转移淋巴结中ERCC1蛋白表达的阳性率为51.7%。个体化治疗组和标准治疗组的化疗有效率分别为58.6%和34.2%（P=0.019），两组的中位生存期分别为9个月和7个月，个体化治疗组的疗效明显优于标准治疗组（P=0.039）。结论 检测淋巴结中ERCC1蛋白的表达以指导NSCLC个体化治疗可以提高化疗效果，延长患者的生存时间。

关键词: 肺肿瘤, 非小细胞肺癌, 核苷酸切除修复交叉互补基因1, 个体化治疗

Abstract: Objective  To detect expression of excision repair cross-complementation group 1（ERCC1） protein in metastatic lymph nodes of patients with advanced non-small cell lung cancer（NSCLC），and investigate whether the expression can be useful for individualizing therapy. Methods A total of 96 patients with pathologically proven NSCLC involving lymph node metastasis were randomized between one group receiving standard treatment group（n=38），which was first-line platinum-based chemotherapy；and another group receiving individualized treatment（n=58），based on ERCC1 protein detection.Treatment effectiveness and Kaplan-Meier survival curves were compared between the two groups. Results ERCC1 protein was expressed in the metastatic lymph nodes of 51.7% of 58 cases.The response rate was significantly higher in the individualized treatment group（58.6%） than in the standard treatment group （34.2%，P=0.019），as was median overall survival（9 vs 7 months，P=0.039）. Conclusions Individualized therapy based on ERCC1 protein detection in metastatic lymph nodes was associated with greater curative effect and survival than was standard therapy.

Key words: Lung neoplasms, Non-small cell lung cancer, Excision repair cross-complementation group 1, Individualized therapy